These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 21669553

  • 1. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
    Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung HP.
    Clin Immunol; 2012 Jan; 142(1):15-24. PubMed ID: 21669553
    [Abstract] [Full Text] [Related]

  • 2. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A, Castilló J, Montalban X.
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [Abstract] [Full Text] [Related]

  • 3. FTY720 (fingolimod) for relapsing multiple sclerosis.
    Horga A, Montalban X.
    Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
    [Abstract] [Full Text] [Related]

  • 4. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
    García-Merino JA, Sánchez AJ.
    Rev Neurol; 2012 Jul 01; 55(1):31-7. PubMed ID: 22718407
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA, Chun J.
    Ann Neurol; 2011 May 01; 69(5):759-77. PubMed ID: 21520239
    [Abstract] [Full Text] [Related]

  • 6. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K, Adachi K.
    Future Med Chem; 2012 Apr 01; 4(6):771-81. PubMed ID: 22530640
    [Abstract] [Full Text] [Related]

  • 7. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW, Choi JW, Chun J.
    Arch Pharm Res; 2010 Oct 01; 33(10):1567-74. PubMed ID: 21052934
    [Abstract] [Full Text] [Related]

  • 8. Central nervous system-directed effects of FTY720 (fingolimod).
    Miron VE, Schubart A, Antel JP.
    J Neurol Sci; 2008 Nov 15; 274(1-2):13-7. PubMed ID: 18678377
    [Abstract] [Full Text] [Related]

  • 9. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L, Vécsei L.
    Ideggyogy Sz; 2012 Mar 30; 65(3-4):83-100. PubMed ID: 23136726
    [Abstract] [Full Text] [Related]

  • 10. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B, Ross AP, Tobias K.
    Int J Clin Pract; 2011 Aug 30; 65(8):887-95. PubMed ID: 21679286
    [Abstract] [Full Text] [Related]

  • 11. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK, Mullershausen F, Mattes H, Kuhn RR, Bilbe G, Hoyer D, Mir A.
    Pharmacol Ther; 2008 Jan 30; 117(1):77-93. PubMed ID: 17961662
    [Abstract] [Full Text] [Related]

  • 12. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA, Kantesaria PP, McDevitt LM.
    Ann Pharmacother; 2007 Oct 30; 41(10):1660-8. PubMed ID: 17785617
    [Abstract] [Full Text] [Related]

  • 13. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kümpfel T, Buck D, Hohlfeld R, Berthele A, Hemmer B.
    Neurology; 2011 Apr 05; 76(14):1214-21. PubMed ID: 21464424
    [Abstract] [Full Text] [Related]

  • 14. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.
    Expert Rev Neurother; 2011 Feb 05; 11(2):165-83. PubMed ID: 21158700
    [Abstract] [Full Text] [Related]

  • 15. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
    Ward MD, Jones DE, Goldman MD.
    Expert Opin Drug Saf; 2014 Jul 05; 13(7):989-98. PubMed ID: 24935480
    [Abstract] [Full Text] [Related]

  • 16. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
    Strader CR, Pearce CJ, Oberlies NH.
    J Nat Prod; 2011 Apr 25; 74(4):900-7. PubMed ID: 21456524
    [Abstract] [Full Text] [Related]

  • 17. Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
    Montalban X, Comi G, O'Connor P, Gold S, de Vera A, Eckert B, Kappos L.
    Mult Scler; 2011 Nov 25; 17(11):1341-50. PubMed ID: 21727148
    [Abstract] [Full Text] [Related]

  • 18. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A.
    Neurology; 2011 Feb 22; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [Abstract] [Full Text] [Related]

  • 19. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J, Hartung HP.
    Clin Neuropharmacol; 2010 Feb 22; 33(2):91-101. PubMed ID: 20061941
    [Abstract] [Full Text] [Related]

  • 20. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Huggins A, Sergott RC.
    Curr Opin Ophthalmol; 2011 Nov 22; 22(6):447-50. PubMed ID: 21946305
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.